Quoin Pharmaceuticals Prices $6.8 Million Equity Offering -- Shares Fall

Published on 20/12/2024 at 16:17 - Modified on 20/12/2024 at 16:28

MT Newswires

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Quoin Pharmaceuticals, Ltd.

Quoin Pharmaceuticals & CFO Gordon Dunn agree to a mutual separation	07-08	RE
Quoin Pharmaceuticals Ltd. Announces Mutual Separation with CFO Gordon Dunn	07-08	CI
Quoin Pharmaceuticals Ltd. Releases New Netherton Now Video Featuring Professor Mellerio, International Expert in Genetic Skin Diseases	06-26	CI
Quoin Pharmaceuticals Ltd. Announces FDA Grants Rare Pediatric Disease Designation for QRX003 in Netherton Syndrome	06-24	CI
Certain Warrants of Quoin Pharmaceuticals, Ltd. are subject to a Lock-Up Agreement Ending on 24-JUN-2025.	06-24	CI
Certain Options of Quoin Pharmaceuticals, Ltd. are subject to a Lock-Up Agreement Ending on 24-JUN-2025.	06-24	CI
Certain American Depositary Shares of Quoin Pharmaceuticals, Ltd. are subject to a Lock-Up Agreement Ending on 24-JUN-2025.	06-24	CI
Certain Ordinary Shares of Quoin Pharmaceuticals, Ltd. are subject to a Lock-Up Agreement Ending on 24-JUN-2025.	06-24	CI
Quoin Pharmaceuticals Ltd. Announces FDA Clearance to Initiate Second Pivotal Whole Body Qrx003 Netherton Syndrome Clinical Study	05-22	CI
Quoin Pharmaceuticals Announces FDA Clearance to Initiate Second Pivotal Whole Body QRX003 Netherton Syndrome Clinical Study	05-22	RE
Quoin Pharmaceuticals Says US FDA Clears Second Netherton Syndrome Pivotal Study	05-22	MT
Quoin Says Early Preliminary Results From Pediatric Skin Disorder Trial Therapy Shows 'Clear Evidence' of Healing	05-14	MT
Quoin Pharmaceuticals Announces Initial Positive Clinical Data for QRX003 from Pediatric Peeling Skin Syndrome Study	05-14	CI
Quoin Pharmaceuticals, Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2025	05-13	CI
Quoin Pharmaceuticals Regains Compliance With Nasdaq	04-30	RE
Quoin Pharmaceuticals Changes ADS Ratio to Meet Nasdaq Rule	04-04	MT
Quoin Pharmaceuticals - Subject's Skin Almost Completely Healed After 6 Weeks Of Qrx003	04-02	RE
Quoin Pharmaceuticals Ltd. Announces Additional Positive 'Whole Body' Clinical Data from Ongoing Pediatric Netherton Syndrome Study and Approval to Initiate Testing of A Second Pediatric Patient	04-02	CI
Quoin Pharmaceuticals Files U.S. Patent Application for Novel Topical Formulations to Treat Netherton Syndrome and Other Skin Diseases	03-25	CI
Quoin Pharmaceuticals, Ltd. Reports Earnings Results for the Full Year Ended December 31, 2024	03-13	CI
Quoin Pharmaceuticals Files U.S. and International Patent Applications for Novel Topical Rapamycin Formulations to Treat Rare Disease Indications	03-04	CI
Quoin Pharmaceuticals Ltd. Announces Highly Positive 'Whole Body' Clinical Data from Ongoing Pediatric Netherton Syndrome Study	02-27	CI
Quoin Pharmaceuticals Ltd. Announces Further Clinical Evidence of QRX003 Effectiveness in Netherton Syndrome	01-23	CI
Quoin Pharmaceuticals Ltd. Announces Positive Clinical Data from its Ongoing Pediatric Netherton Syndrome Study	01-16	CI
Quoin Pharmaceuticals Ltd. Announces Additional Positive Interim Data from Ongoing Open-Label Netherton Syndrome Clinical Study	01-06	CI